Bayer Agrees to Suspend Marketing of Trasylol
November 5, 2007 09:28

WASHINGTON, D.C. -- The FDA said today that Bayer Pharmaceuticals Corp. has agreed to an agency request to suspend marketing of the company's Trasylol blood-clotting drug because of an increased risk of death.

Subject: MedEffect/MedEffet - Trasylol
November 5, 2007 09:33

Manufacturer temporarily suspends marketing of Trasylol in Canada - Consumer InformationHealth Canada has requested that Bayer Inc., maker of Trasylol, temporarily suspend sales of Trasylol (aprotinin) until a review is completed of results from the BART study.... (Read Article)

FDA Requests Marketing Suspension of Trasylol
November 5, 2007 10:46

FDA Requests Marketing Suspension of TrasylolThe U.S. Food and Drug Administration (FDA) today announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart... (Read Article)

Bayer Agrees to Withdraw Heart Surgery Drug - Trasylol
November 6, 2007 04:45

German pharmaceutical manufacturer, Bayer AG, agreed to withdraw the heart surgery drug Trasylol after the Canadian BART study suggested increased death rates. The Canadian study was cut short when a statistically sigfnificant death rate was found in the data.... (Read Article)